一、 本次股东大会的召集与召开程序 本次股东大会由公司第八届董事会第十三次会议决议召集。公司于 2025 年 4 月 26 日在《中国证券报》《证券时报》《证券日报》及巨潮资讯网 （www.cninfo.com.cn）上公告了《关于召开 2024 年度股东大会的通知》（以下 简称"会议通知"），会议通知载明了本次股东大会的召开时间和地点、投票方 式、会议召开方式、股权登记日、出席人员、会议审议事项和提案、会议登记相 关事项等内容。 本次股东大会采取现场表决和网络投票相结合的表决方式。本次股东大会现 场会议于 2025 年 5 月 16 日 14:30 在广西桂林市临桂区人民南路 9 号公司四楼会 议室如期举行。网络投票时间为：（1）通过深圳证券交易所交易系统进行网络 投票的具体时间为：2025 年 5 月 16 日 9:15-9:25，9:30-11:30 和 13:00-15:00；（2） 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025 年 5 月 16 日 9:15-15:00 期间的任意时间。 关于桂林三金药业股份有限公司 2024 年 ...

Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system and a professional data analysis team to balance market demand dynamics and cost control [1] - The overall inventory level has significantly decreased compared to the same period last year, maintaining a healthy inventory cycle of 1.5 to 2 months [1] Product Growth Potential - The growth trend for the company's second and third-line products is positive, with specific products like the Hejia Danchuan capsule expected to maintain last year's growth rate [1] - The Xuanyunning series has surpassed 100 million in sales in 2021, aiming for double-digit growth this year [1] - Other products, such as Shuyanquing spray and Fufang Ganmaoling granules, are also expected to maintain high growth rates [1] Dividend Policy - The company has consistently implemented a cash dividend policy, proposing a cash dividend of 3.5 yuan per 10 shares for 2024, totaling 206 million yuan [2] - The dividend policy is expected to remain stable unless there are special funding needs [2] Biopharmaceutical Development - Biopharmaceuticals are a key part of the company's dual strategy, facing high investment and risk, with the industry currently experiencing a downturn [2] - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal antibody injection, which is nearing the completion of Phase I clinical trials [2] - Efforts are being made to control costs and expenses while seeking partnerships in the biopharmaceutical sector [2]

证券代码：002275 证券简称：桂林三金 编号：2025-020 桂林三金药业股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示 1.本次股东大会未出现否决提案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1.召开时间： （1）现场会议召开时间：2025年5月16日14:30； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2025年5 月16日9:15—9:25,9:30—11:30 和13:00—15:00；通过深圳证券交易所互联网 投票系统（http://wltp.cninfo.com.cn）投票时间为2025年5月16日9:15-15:00 期间的任意时间。 2.现场会议召开地点：广西壮族自治区桂林市临桂区人民南路9号公司四楼 会议室 3.召开方式：现场投票与网络投票相结合的方式 4.召集人：公司董事会 5.主持人：董事长邹洵先生 6.公司已于2025年4月26日在《中国证券报》《证券时报》《证券日报》及 巨潮资讯网发布了《关于召开2024年度股东大会的 ...

证券代码：002275 证券简称：桂林三金 公告编号：2025-019 桂林三金药业股份有限公司 关于召开2024年度业绩说明会并征集问题的公告 2.召开方式：网络远程文字交流的方式。 3. 参 与 方 式 ： 投 资 者 可 登 录 深 圳 证 券 交 易 所 " 互 动 易 " 平 台 （http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次年度业绩说明会。 4.公司出席人员：董事长、总裁邹洵先生，董事、副总裁兼财务负责人谢元 钢先生，副总裁兼董事会秘书李春先生，独立董事陈亮先生。 二、投资者问题征集事宜 为充分尊重投资者、提升交流的针对性，现就公司2024年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可在本次业绩说 明会召开前登录深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn） 进入"业绩说明会提问预征集"专题页面或扫描下方二维码提交问题，公司将在 2024年度业绩说明会上对投资者普遍关注的问题进行回答。业绩说明会召开交流 期间，投资者仍可登录活动界面进行互动提问。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 ...

Core Viewpoint - The company has shown growth in revenue and profit for the fiscal year 2024, but faces challenges in its biopharmaceutical segment due to a competitive environment and high R&D costs [2][3]. Financial Performance - In 2024, the company achieved total revenue of 2.19 billion yuan, a 1.03% increase from 2.17 billion yuan in the previous year [2]. - Profit before tax reached 643.94 million yuan, up 24.24% from 518.28 million yuan year-on-year [2]. - Net profit attributable to shareholders was 521.53 million yuan, reflecting a 23.79% increase from 421.30 million yuan [2]. - In Q1 2025, the company reported a net profit of 97.67 million yuan, an 11.61% increase from 87.52 million yuan in the same period last year [2]. Biopharmaceutical Segment - The biopharmaceutical sector is a key part of the company's strategy but is currently facing a cooling market with high competition and investment risks [2][3]. - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal antibody injection, which is nearing completion of Phase I clinical trials [3]. Inventory and Sales Management - The company has improved its inventory management through a BI intelligent analysis system, achieving a healthier inventory cycle of 1.5 to 2 months [5]. - The company has implemented diverse promotional activities to stimulate end-market consumption and optimize inventory structure [5]. Product Development - The company is optimistic about the growth potential of its second and third-tier products, with specific products like the Guaifenesin capsule and the dizziness relief series expected to maintain or achieve significant growth [6]. Dividend Policy - The company has a consistent cash dividend policy, proposing a cash dividend of 0.35 yuan per share for 2024, totaling 206 million yuan [8]. - The company aims to maintain stable operating cash flow to support its dividend policy unless special funding needs arise [7]. Sales Expense Management - The company has been strict in controlling sales expenses, focusing on second and third-tier products while maintaining a balanced sales expense ratio [9].

Financial Performance - In 2024, the company achieved total revenue of 2,193.99 million CNY, a growth of 1.03% compared to 2023's 2,171.60 million CNY [1] - The total profit reached 643.94 million CNY, an increase of 24.24% from 518.28 million CNY in the previous year [1] - Net profit attributable to shareholders was 521.53 million CNY, up 23.79% from 421.30 million CNY year-on-year [1] - In Q1 2025, the net profit after deducting non-recurring gains and losses was 97.67 million CNY, reflecting an 11.61% increase from 87.52 million CNY in Q1 2024 [1] Business Development - The biopharmaceutical sector is a key part of the company's dual-wing strategy, facing high investment and long R&D cycles, with current market conditions being challenging [1] - The company is experiencing increased competition and a diverse customer base, leading to some idle capacity in the CDMO supply chain [1] - Ongoing projects in the biopharmaceutical pipeline are still in the R&D phase, with limited revenue from technical services [1] - The company is optimizing costs and personnel structure while focusing on promising projects, such as the BC006 monoclonal antibody injection, which is nearing completion of Phase I clinical trials [1] Inventory and Sales Management - The company has upgraded its inventory management system, utilizing BI analytics to enhance market demand alignment and cost control [2] - The overall inventory level has improved significantly, maintaining a healthy cycle of 1.5 to 2 months, which supports operational quality and cost optimization [2] - The company has implemented diverse promotional activities to stimulate market demand and optimize inventory across channels [2] Product Growth and Dividends - The growth trend for second and third-tier products remains positive, with specific products like the Guaifenesin capsule expected to continue strong growth [2] - The company plans to maintain its cash dividend policy, proposing a distribution of 3.5 CNY per 10 shares, totaling 206 million CNY for 2024 [2] Sales Expense Management - The company has adopted a more precise approach to sales expense allocation, focusing on second and third-tier products while maintaining a low expense ratio for first-tier products [3] - Overall sales expenses are aligned with sales revenue, indicating no significant changes in the sales expense ratio for the year [3]

Group 1 - Kexin Technology plans to repurchase shares worth between 30 million and 50 million yuan, with a maximum repurchase price of 80 yuan per share, for employee stock ownership plans or capital reduction [1] - Jiahua Technology's shareholder plans to reduce holdings by up to 1.5% of the company's total shares, amounting to a maximum of 116,000 shares, between May 28, 2025, and August 25, 2025 [1] - Beiqi Blue Valley's subsidiary reported cumulative sales of 38,041 vehicles this year, representing a year-on-year increase of 192.53% [2] Group 2 - AVIC Finance plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Onboard Systems, totaling 4.067 billion yuan, to its controlling shareholder [2] - Haide shares' executives plan to increase their holdings by at least 20.73 million yuan within six months [3] - Dabeinong's subsidiary received planting approval for genetically modified soybeans in Brazil, marking significant progress in the South American market [4] Group 3 - Yongan Pharmaceutical's chairman is under investigation, but the company's operations remain normal [4] - Teruid's subsidiary is expected to win a 126 million yuan project from the State Grid, which will enhance the company's brand and industry influence [4][5] - Junxin shares plan to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 30.57 yuan per share [5] Group 4 - Meinian Health plans to reduce its holdings by up to 3% of the company's total shares, amounting to a maximum of 11.7 million shares, starting from May 27, 2025 [7] - Electric Power Investment is planning a major asset restructuring, leading to a temporary suspension of its stock [9] - Tongda shares are expected to win a 207 million yuan project from the State Grid, which will positively impact future operating performance [10] Group 5 - Xintian Technology's major shareholder plans to reduce holdings by up to 3% of the company's total shares, amounting to a maximum of 580,410 shares [11] - Huizhou Intelligent's controlling shareholder and some executives plan to increase their holdings by between 29.2 million and 58.4 million yuan [12] - Zhongdali De plans to sell a 50% stake in Shanghai Ketaike Transmission System Co., Ltd. for 9.2777 million yuan to optimize its asset structure [14] Group 6 - Jinlitai's stock will be suspended due to the inability to disclose periodic reports within the statutory deadline [15] - Chuhuan Technology's major shareholder plans to reduce holdings by up to 3% of the company's total shares, amounting to a maximum of 239,560 shares [15] - Guilin Sanjin's subsidiary received approval for clinical trials of a new indication for a monoclonal antibody injection [16] Group 7 - Plit plans to sign a strategic supply agreement for sodium-ion batteries, committing to supply at least 1 GWh over four years [17] - Dalian Electric Porcelain's subsidiary is expected to win a project worth approximately 71 million yuan from the State Grid [18]

证券代码：002275 证券简称：桂林三金 公告编号：2025-018 桂林三金药业股份有限公司 关于控股孙公司 BC006 单抗注射液新增适应症获得药 物临床试验批准的公告 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 2 月 17 日受理的 BC006 单抗注射液临床试验申请符合药品注册的有关要求， 同意本品开展用于特发性肺纤维化适应症的临床试验。 二、该药品研发及相关情况 公司已于 2021 年 3 月收到国家药品监督管理局核准签发的 BC006 单抗注射 液的临床试验批件，拟用于治疗晚期恶性肿瘤，有望解决在多种实体瘤、血液肿 瘤、骨关节疾病等疾病领域未能满足的医疗需求。详细内容见公司于 2021 年 3 月 22 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于控股孙公司 获得药物临床试验批准的公告》（公告编号：2021-002）。该适应症临床试验目前 处于 I 期临床试验进行中。 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 近日，桂林三金药业股份有限公司（以下简称"公司"）控 ...

Group 1: Financial Performance - In 2024, the company achieved total revenue of 2,193.99 million yuan, a 1.03% increase from 2,171.60 million yuan in the previous year [1] - The total profit reached 643.94 million yuan, up 24.24% from 518.28 million yuan year-on-year [1] - The net profit attributable to shareholders was 521.53 million yuan, reflecting a 23.79% growth compared to 421.30 million yuan in the previous year [1] - In Q1 2025, the net profit excluding non-recurring gains and losses was 97.67 million yuan, an 11.61% increase from 87.52 million yuan in the same period last year [1] Group 2: Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system to enhance efficiency [1] - The inventory turnover period is maintained at a healthy level of 1.5 to 2 months, indicating effective inventory control [1] - Overall inventory levels have significantly decreased compared to previous years, supporting operational quality and cost optimization [1] Group 3: Product Development and Market Trends - The company expects good growth trends for its second and third-line products, with specific products like Hakeke Dinhua Capsules anticipated to maintain last year's growth rate [2] - The sales of the Xuanyun Ning series surpassed 100 million yuan in 2021, with a target of achieving double-digit growth this year [2] - The company is focusing on optimizing its R&D pipeline, particularly for promising projects like the BC006 monoclonal antibody injection, which is nearing the completion of Phase I clinical trials [2] Group 4: Sales and Marketing Strategy - The company is adopting a more precise approach to sales expenses, with a focus on second and third-line products [2] - Sales expenses are expected to align with sales revenue, maintaining a stable sales expense ratio throughout the year [2] - The promotion of Sanjin Granules in hospitals is progressing well, although its overall contribution to sales remains limited due to a small base [3] Group 5: Dividend Policy - The company has a consistent cash dividend policy, proposing a distribution of 3.5 yuan per 10 shares, totaling 206 million yuan for 2024 [3] - The dividend policy is subject to the company's operational needs and sustainable development capabilities [3]

桂林三金药业股份有限公司 独立董事2024年度述职报告 作为桂林三金药业股份有限公司（以下简称"公司"）董事会独立董事，2024 年，本人严格按照《公司法》《上市公司独立董事管理办法》《深圳证券交易所 上市公司自律监管指引第1号——主板上市公司规范运作》等法律法规及《公司 章程》《独立董事工作制度》的规定，本着客观、公正、独立的原则，勤勉尽责， 充分发挥独立董事作用，维护了公司整体利益和全体股东尤其是中小股东的合法 权益。现将2024年度本人履行职责的情况报告如下： 一、基本情况 （一）个人工作履历、专业背景以及兼职情况 本人莫凌侠，1964年出生，1989年毕业于西南政法大学民法专业，法学硕士， 为广西师范大学法学院教授，主要研究方向为民商法、公司法、证券法、知识产 权法等领域。本人于1991年开始兼职律师执业，先后担任数十家国家机关、大型 企、事业单位的法律顾问，同时兼任桂林仲裁委员会仲裁员。本人自2019年4月 开始担任公司独立董事，因连续任职满6年于2025年4月12日离任公司独立董事。 （二）不存在影响独立性的情况说明 本人符合《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》 《上市公司自 ...